Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence

References

• Ziai WC, Lewin JJ 3rd. Update in the diagnosis and management of central nervous system infections. Neurol Clin. 2008 May;26(2):427–468.
   PubMed Web of Science ®Google Scholar
• Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med. 1998 Dec 1;129(11):862–869.
   PubMed Web of Science ®Google Scholar
• Nau R, Djukic M, Spreer A, et al. Bacterial meningitis: an update of new treatment options. Expert Rev Anti Infect Ther. 2015;13(11):1401–1423.
   PubMed Web of Science ®Google Scholar
• Lu CL, Liu CY, Huang YT, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 2011 Sep;55(9):4295–4301. .
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents. 2010 May;35(5):497–499.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):439–443. .
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010 Mar;35(3):240–243.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010 Jan;10(1):43–50. .
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010 Feb;16(2):184–186.
   PubMed Web of Science ®Google Scholar
• Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012 Mar;44(3):182–189.
   PubMed Web of Science ®Google Scholar
• Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016 May;22(5):273–280.
   PubMed Web of Science ®Google Scholar
• Kuhnen E, Pfeifer G, Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection. 1987 Nov-Dec;15(6):422–424. .
   PubMed Web of Science ®Google Scholar
• Sauermann R, Karch R, Langenberger H, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005 Nov;49(11):4448–4454. .
   PubMed Web of Science ®Google Scholar
• Putensen C, Ellger B, Sakka SG, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019 Oct;47(5):827–836. .
   PubMed Web of Science ®Google Scholar
• Sicilia T, Fadon A, Rodriguez A, et al. Fosfomycin in pneumococcal meningitis. Chemotherapy. 1977;23(Suppl 1):429–440.
   PubMedGoogle Scholar
• Sakka SG, Schmidt K, Jaschinski LS, et al. (IV) Fosfomycin for the treatment of patients with central nervous system infection – insights from the NIS-FOM study and literature review. Arbeitstagung NeuroIntensivMedizin ANIM2019.
   Google Scholar
• Tritthart DH. Fosfomycin in cerebral and spinal abscesses. In: Guggenbichler DDJ-P, editor. New aspects for treatment with fosfomycin. Wien New York: Springer-Verlag; 1987:58-66.
   Google Scholar
• Longuet P, Vallee E, Michel M, et al. [Vancomycin in meningitis caused by penicillin G resistant Streptococcus pneumoniae]. Presse Med. 1993 Nov 20;22(36):1818–1819.
   PubMed Web of Science ®Google Scholar
• Portier H, Tremeaux JC, Chavanet P, et al. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother. 1984 Sep;14(Suppl):B:277–84.
   PubMedGoogle Scholar
• Seto C, Ikeda A, Ohkawa M. [A case report of urinary tract infection and meningitis caused by methicillin-resistant Staphylococcus aureus (MRSA) after transurethral resection of the prostate]. Nihon Hinyokika Gakkai Zasshi. 1999 Mar;90(3):466–469.
   PubMedGoogle Scholar
• Inoue Y, Ohtsubo T, Mori N, et al. [A case of Campylobacter fetus subspecies fetus meningitis]. Kansenshogaku Zasshi. 1993 Jan;67(1):66–70. .
   PubMedGoogle Scholar
• Silbermann MH, Gyssens IC, Wielenga JJ, et al. [A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin]. Ned Tijdschr Geneeskd. 1995 Dec 2;139(48):2498–2501.
   PubMedGoogle Scholar
• Frattari A, Savini V, Polilli E, et al. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: case report and review of the literature. IDCases. 2018;14:e00451.
   Google Scholar
• Faye A, Mariani-Kurkjian P, Taha MK, et al. [Clinical aspects and outcome of meningococcal disease due to Neisseria meningitidis of serogroup W135 in 5 children]. Arch Pediatr. 2005 Mar;12(3):291–294.
   PubMed Web of Science ®Google Scholar
• Portier H, Armengaud M, Becq-Giraudon B, et al. [Treatment with a cefotaxime-fosfomycin combination of staphylococcal or enterobacterial meningitis in adults]. Presse Med. 1987 Dec 16;16(43):2161–2166.
   PubMed Web of Science ®Google Scholar
• Stahl JP, Croize J, Bru JP, et al. [Diffusion of fosfomycin into the cerebrospinal fluid in purulent meningitis]. Presse Med. 1984 Dec 8;13(44):2693–2695.
   PubMed Web of Science ®Google Scholar
• Friedrich H, Engel E, Potel J. [Fosfomycin levels in the cerebrospinal fluid of patients with and without meningitis]. Immun Infekt 1987 May;15(3):98–102.
   PubMedGoogle Scholar
• May T, Weber M, Gerard A, et al. [Treatment of post-traumatic and post-neurosurgical bacterial meningitis with ceftriaxone alone or in combination with fosfomycin]. Pathol Biol. 1987 Jun;35(5 Pt 2):839–842.
   PubMedGoogle Scholar
• Mellon G, Clec’h C, Picard B, et al. Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother. 2012 Dec;18(6):958–960.
   PubMed Web of Science ®Google Scholar
• Furuya N, Shimozi K, Nakamura H, et al. [A case report of meningitis and sepsis due to Enterococcus faecium complicated with strongyloidiasis]. Kansenshogaku Zasshi. 1989 Dec;63(12):1344–1349. .
   PubMedGoogle Scholar
• Hansen N, Seiler C, Rumpf J, et al. Human tuberculous meningitis caused by mycobacterium caprae. Case Rep Neurol. 2012 Jan;4(1):54–60. .
   PubMedGoogle Scholar
• Sakamoto T, Kikuchi K, Mineura K, et al. MRSA meningitis in postoperative patients. Report of 4 cases. Jpn J Antibiot 1990 Jun;43(6):1137–1142.
   PubMedGoogle Scholar
• Sicilia T, Estevez E, Rodriguez A. Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis. Chemotherapy. 1981;27(6):405–413.
   PubMed Web of Science ®Google Scholar
• Tremeaux JC, Duez JM, Pechinot A, et al. [Importance of the cefotaxime-fosfomycin combination. Apropos of a case of meningitis due to heterogeneously resistant Staphylococcus aureus]. Agressologie. 1983 Apr;24(4):169–171.
   PubMedGoogle Scholar
• Nusko G, Dertinger S, Cidlinsky K, et al. [Presacral phlegmons and meningitis as the complications of a foreign body in the rectosigmoid]. Dtsch Med Wochenschr. 1994 Jul 15;119(28–29):990–993.
   PubMed Web of Science ®Google Scholar
• Stahl JP, Croize J, Baud A, et al. [Treatment of neurosurgical bacterial meningitis using the combination of ceftriaxone-fosfomycin]. Pathol Biol. 1986 May;34(5):479–482.
   PubMedGoogle Scholar
• Sonntag J, Kaczmarek D, Brinkmann G, et al. [Complicating neonatal escherichia coli meningitis]. Z Geburtshilfe Neonatol. 2004 Feb;208(1):32–35.
   PubMedGoogle Scholar
• Lee WS, Wang FD, Shieh YH, et al. Lemierre syndrome complicating multiple brain abscesses caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae cured by fosfomycin and meropenem combination therapy. J Microbiol Immunol Infect. 2012 Feb;45(1):72–74.
   PubMedGoogle Scholar
• Algubaisi S, Buhrer C, Thomale UW, et al. Favorable outcome in cerebral abscesses caused by Citrobacter koseri in a newborn infant. IDCases. 2014;2(1):22–24.
   PubMed Web of Science ®Google Scholar
• Trummer M, Eustacchio S, Unger F. Prognose und Therapie posttraumatischer intrakranieller Abszesse und Empyeme. Acta Chirurgica Austriaca. 1999;31(1):32–35.
   Google Scholar
• Gimeno L. Neurosurgical infection treated with fosfomycin and 6-methylprednisolone. Chemotherapy. 1977;23(Suppl 1):399–402.
   PubMedGoogle Scholar
• Berner R, Heinen F, Pelz K, et al. Ventricular shunt infection and meningitis due to Bacillus cereus. Neuropediatrics. 1997 Dec;28(6):333–334.
   PubMed Web of Science ®Google Scholar
• Boulard G, Quentin C, Scontrini G, et al. [Treatment of ventriculitis caused by Staphylococcus epidermidis on equipment with the combination of fosfomycin and an aminoglycoside. Course of ventricular levels of fosfomycin]. Pathol Biol (Paris). 1983 Jun;31(6):525–527.
   PubMedGoogle Scholar
• Fosse T, Peloux Y, Granthil C, et al. Meningitis due to Micrococcus luteus. Infection. 1985 Nov-Dec;13(6):280–281.
   PubMed Web of Science ®Google Scholar
• Tseng YC, Kan LP, Huang LY, et al. Successful treatment of a patient with ventriculoperitoneal shunt-associated meningitis caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Tohoku J Exp Med. 2014 Aug;233(4):301–305. .
   PubMed Web of Science ®Google Scholar
• van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016 May;22(Suppl 3):S37–62. .
   PubMed Web of Science ®Google Scholar
• Nau R. S1-Leitlinie Hirnabszess. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. 2016. [cited 2019 Dec 12]. Available from: www.dgn.org/leitlinienwww.dgn.org/leitlinien.
   Google Scholar
• Pfister HW Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter. 2015. [cited 2019 Dec 12]. Available from: https://www.dgn.org/images/red_leitlinien/LL_2015/PDFs_Download/030-089l_S2k_Ambulant_erworbene_Meningoenzephalitis_2016-08-verlaengert_01.pdf
   Google Scholar
• Limited NP. Fomicyt 40mg/ml powder for solution for infusion 2017. Available from: https://www.medicines.org.uk/emc/product/5439/smpc
   Google Scholar
• Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004 May;53(5):848–852.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Karageorgopoulos DE, et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009 Aug;34(2):111–120.
   PubMed Web of Science ®Google Scholar
• Blassmann U, Roehr AC, Frey OR, et al. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care. 2016 Oct 24;20(1):343.
   PubMedGoogle Scholar
• Chew R, Woods ML. Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against meticillin-sensitive Staphylococcus aureus in adults: A case report and review of the literature. Int J Antimicrob Agents. 2016 Mar;47(3):229–231.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Nau R, Kinzig M, et al. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother. 2007 Nov;60(5):1038–1044.
   PubMed Web of Science ®Google Scholar
• Grabein B, Graninger W, Rodriguez Bano J, et al. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017 Jun;23(6):363–372.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Wang R, Yu X-H, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012 Feb;67(2):255–268.
   PubMed Web of Science ®Google Scholar
• Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.. Pharmacotherapy. 1995 May-Jun;15(3):279–291.
   PubMed Web of Science ®Google Scholar
• Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol. 1987 6;6(3):234–244. .
   PubMedGoogle Scholar
• Wei W, Yang H, Liu Y, et al. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother. 2016 Jun;28(3):159–163.
   PubMed Web of Science ®Google Scholar
• Descourouez JL, Jorgenson MR, Wergin JE, et al. Fosfomycin Synergy In Vitro with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant Enterococcus faecium from Renal Transplant Patients with Infected Urinary Stents. Antimicrob Agents Chemother. 2013 Mar;57(3):1518–1520.
   PubMed Web of Science ®Google Scholar
• Hauser C, Hirzberger L, Unemo M, et al. In Vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical neisseria gonorrhoeae isolates. Antimicrob Agents Chemother. 2015 Mar;59(3):1605–1611.
   PubMed Web of Science ®Google Scholar
• Santos DA, Nascimento MM, Vitali LH, et al. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. Rev Soc Bras Med Trop. 2013 May-Jun;46(3):299–303.
   PubMed Web of Science ®Google Scholar
• Xu-hong Y, Falagas ME, Dong W, et al. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo). 2014 May;67(5):369–371.
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012 May;31(5):695–701.
   PubMed Web of Science ®Google Scholar
• Del Rio A, Gasch O, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis. 2014 Oct 15;59(8):1105–1112.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Rice LB, Dane A, et al. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019 Nov 27;69(12):2045–2056.
   Web of Science ®Google Scholar
• Rosso-Fernandez C, Sojo-Dorado J, Barriga A, et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015 Mar 31;5(3):e007363.
   PubMed Web of Science ®Google Scholar
• Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis. 2004 Nov 1;39(9):1314–1320.
   PubMed Web of Science ®Google Scholar
• Grif K, Dierich MP, Pfaller K, et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother. 2001 Aug;48(2):209–217.
   PubMed Web of Science ®Google Scholar